GranuFlo, NaturaLyte, Heart Attack Allegations Alert: Resource4thePeople Announces Continuation of Free Consultations for Consumers in 2014

National network of attorneys will resume availability in connection with consumer inquiries over allegations that dialysis products caused life-threatening heart attacks. Number of federal lawsuits consolidated over these allegations continues to climb.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

San Diego, CA (PRWEB) January 08, 2014

http://www.resource4thepeople.com/defectivemedicaldevices/Dialysis-Lawsuit.html

Resource4thePeople today announced today that its national network of attorneys will continue to offer no-cost consultations in 2014 to consumers who are seeking compensation involving allegations contained in GranuFlo and NaturaLyte lawsuits over life-threatening heart problems.

“We are proud to announce that our policy of providing these consultations to consumers inquiring about heart attack concerns raised by the Food and Drug Administration* and the legal options available to seek compensation will be resumed in 2014,” said Resource4thePeople.

The announcement was made after numerous inquiries were received from consumers about whether the Resource4thePeople national network of attorneys would continue to offer these consultations involving heart attack concerns after 2013, said Resource4thePeople.

“The continued increase in the number of consumers inquiring about alleged GranuFlo and NaturaLyte side effects since the FDA issued a Class 1 Recall over heart attack concerns shows that there are a great number of affected consumers seeking experienced, aggressive legal help,” said Resource4thePeople.

GranuFlo and NaturaLyte were the subject of a the Class 1 Recall issued on March 29, 2012 in which federal officials spelled out details of why the recall was made over concerns about life-threatening heart problems for patients:

“The manufacturer is cautioning clinicians to be aware of the concentration of acetate or sodium diacetate (acetic acid plus acetate) contained in Fresenius' NaturaLyte Liquid and GranuFlo Dry Acid Concentrate. Inappropriate prescription of these products can lead to a high serum bicarbonate level in patients undergoing hemodialysis,” the FDA said.

“This may contribute to metabolic alkalosis, which is a significant risk factor associated with low blood pressure, hypokalemia, hypoxemia, hypercapnia and cardiac arrhythmia, which, if not appropriately treated, may culminate in cardiopulmonary arrest. This product may cause serious adverse health consequences, including death.”

These concerns have generated numerous GranuFlo and NaturaLyte lawsuits ** from across the country that have been consolidated before a federal judge over allegations that NaturaLyte and GranuFlo dialysis products caused heart attacks and, in some cases, deaths.

Recent figures*** show that the number of NaturaLyte and GranuFlo lawsuits that have been combined in the federal multidistrict litigation in U.S. District Court of Massachusetts has increased to 393.

"This multidistrict litigation is still in the early stages but the increase in the number of cases shows that we can expect more such cases to be filed in the future," said Resource4thePeople.

"We will continue our commitment to assist consumers who have been affected by these allegations by maintaining our policy of no-cost consultations that will enable them to determine what legal options they may have to seek compensation in such cases."

Resource4thePeople's national network of attorneys are answering questions from consumers who are alleging that they suffered cardiac arrest, heart attacks, strokes, sudden cardiac death and other side effects in connection with the allegations currently filed in the multidistrict litigation.

The docket of the multidistrict litigation** in the U.S. District Court of Massachusetts summarizes the specific allegations involved:

“These actions share factual issues arising from allegations that Plaintiffs suffered injury or death caused by the use of GranuFlo and/or NaturaLyte products during hemodialysis, which allegedly may cause metabolic alkalosis in patients resulting in low blood pressure, hypokalemia, hypoxemia, hypercapnia, cardiac arrhythmia, or cardiopulmonary arrest.

“All the actions involve factual questions relating to whether GranuFlo and NaturaLyte were defectively designed or manufactured, whether Fresenius, the manufacturer of these dialysate products, knew or should have known of the alleged propensity of these products to cause injury and whether it provided adequate instructions and warnings with these products.”

The court docket in the cases before Judge Woodlock also shows that the court has begun the process of directing the lawyers in their pre-trial evidence-gathering and other legal requirements.

Meanwhile, a group of state court cases**** containing similar NaturaLyte and GranuFlo allegations filed in Massachusetts have been consolidated in similar fashion before a single state court judge in Middlesex County.

Resource4thePeople also is informing consumers that as this litigation advances more lawsuits continue to be filed against Fresenius over similar allegations involving GranuFlo and NaturaLyte products.

One of the most recent was filed by the husband of a woman who, according to the allegations in the court file,***** died as a result of her dialysis treatment with NaturaLyte and/or GranuFlo.

His lawyers are claiming that Fresenius officials knew that serious heart problems might be a side effect of the treatment but failed to adequately warn consumers and health care providers, according to the court file.

The FDA describes Class I Recalls as the most serious type of recall involving situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death.

According to the FDA, the affected NaturaLyte and GranuFlo Dry Acid concentrates were manufactured between January 2008 and June 2012 and are used in the treatment of acute and chronic renal failure during hemodialysis.

Meanwhile, FDA records show that Fresenius was cited****** by federal regulators over deficiencies uncovered at one of the company’s facilities.

In a warning letter dated March 13, 2013, FDA officials informed Fresenius Medical Care officials that dialyzers manufactured at the company’s Ogden, Utah plant did not meet current federal good manufacturing requirements.

Sources:
*http://www.fda.gov/medicaldevices/safety/listofrecalls/ucm309990.htm
**In re Fresenius GranuFlo/NaturaLyte Dialysate Litigation 13-md-02428, U.S. District Court of Massachusetts, Judge Douglas P. Woodlock
***http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-November-18-2013.pdf
****In re Consolidated Fresenius Cases, No. MICV2013-03400-O, Middlesex County Superior Court, Judge Maynard M. Kirpalani
*****Case # 2:13cv20858, Harris v. Fresenius, U.S. District Court for the Southern District of Virginia, Judge Paul Zakaib Jr.
******http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm344711.htm


Contact

  • Bill Callahan
    iLawSuit
    +1 858 602-2749
    Email